A Phase 2, Single Arm, Multicohort, Open Label, Multicenter Trial of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Patients With High-risk Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 08 Mar 2024
At a glance
- Drugs SAR 445419 (Primary) ; Cyclophosphamide; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Sanofi
- 04 Mar 2024 Planned End Date changed from 17 Feb 2027 to 11 Oct 2027.
- 04 Mar 2024 Planned primary completion date changed from 17 Feb 2027 to 12 Feb 2027.
- 04 Mar 2024 Planned initiation date changed from 23 Feb 2024 to 8 Oct 2024.